Journal of Infectious Diseases & Therapy
Open Access

Abstract

Antibiotic resistance is a worldwide health problem. Antibiotic resistance can increase rate of mortality and morbidity especially in immunosuppress patients like hospitalized one. Antibiotic-resistant infections add considerable costs to the nation’s already overburdened health care system. Estimates regarding the medical cost per patient with an antibiotic-resistant infection range from $ 18,588 to $ 29,069 in 2015. The total economic burden placed on the US economy by antibioticresistant infections has been estimated to be as high as $ 20 billion in health care costs. It can be considerable that making and introducing new antibiotics are very low because there is no economic justification because of early appearance of resistance. The most critical group of all includes multidrug resistant bacteria that pose a particular threat in hospitals, nursing homes and among patients whose care requires devices such as ventilators and blood catheters. They include Acinetobacter, Pseudomonas and various Enterobacteriaceae (including Klebsiella, E. coli, Serratia and Proteus). They can cause severe and often deadly infections such as bloodstream infections and pneumonia. WHO priority pathogens list for R&D of new antibiotics: Priority 1: Critical Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant, ESBL-producing Priority 2: High Enterococcus faecium, vancomycin-resistant Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant Priority 3: Medium Streptococcus pneumoniae, penicillin-non-susceptible So, in this report we explain about rate of present and also antibiotic resistance patterns of these global threating bacteria in Iran as an Asian country.

Biography

E-mail: leilaazimi1982@gmail.com